Radella Pharmaceuticals in the US has released promising Phase Ia trial results for MD-18, a novel therapy targeting PTP1B to improve glucose regulation and energy metabolism. The trial demonstrated safety, tolerability, and metabolic improvements in healthy participants, paving the way for further clinical studies.